Welcome to our dedicated page for Inspira Technologies OXY B.H.N. SEC filings (Ticker: IINN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inspira Technologies Oxy B.H.N. Ltd. filings document foreign-private-issuer current reports, shareholder meeting materials and registration statement incorporation for its technology business. Form 6-K reports furnish press releases on AME system orders, commercial deployments, the QTREX platform, cryogenic interconnect development and shareholder communications, while proxy materials cover voting matters such as amendments to the company's articles of association.
Other filings describe governance and officer appointments, ordinary-share voting procedures, Form F-3 and Form S-8 registration statement references, and capital-structure context tied to the company's Nasdaq-listed securities and medical technology operations.
Inspira Technologies Oxy B.H.N. Ltd. entered a definitive agreement with a single institutional investor for a registered direct offering and concurrent private placement expected to raise approximately $4.75 million before fees. The company will sell 4,000,000 ordinary shares at $0.70 per share and pre-funded warrants for up to 2,785,715 shares at $0.6999 each, plus ordinary warrants to purchase up to 6,785,715 shares at $0.70 in a private placement.
The pre-funded warrants are exercisable immediately at $0.0001 per share, while the ordinary warrants become exercisable six months after issuance and expire five years after first exercise. Inspira also agreed to reduce the exercise price of 3,031,250 existing warrants from $1.28 to $0.70 and extend their expiration to February 5, 2031. Net proceeds are intended for working capital and general corporate purposes.
Inspira Technologies Oxy B.H.N. Ltd. is registering 6,785,715 ordinary share equivalents through a direct offering of 4,000,000 ordinary shares and pre-funded warrants to purchase up to 2,785,715 additional shares at combined prices around $0.70 per paired security and warrant.
In a concurrent private placement, the same investor will receive unregistered warrants to purchase up to 6,785,715 ordinary shares at an exercise price of $0.70, exercisable six months after issuance for five and a half years. The transaction is expected to generate gross proceeds of $4,749,721 and approximately $4.3 million in net proceeds, which the company plans to use for working capital and general corporate purposes.
Ordinary shares outstanding are expected to increase from 37,074,123 to 43,859,838 assuming full exercise of the pre-funded warrants, resulting in meaningful dilution for existing shareholders. The company also agreed to reduce the exercise price and extend the term of 3,031,250 existing warrants, further expanding potential future share issuance.
Inspira Technologies filed a Form 6-K highlighting new validation data for its next-generation standalone HYLA™ blood sensor system. In advanced lab testing, HYLA achieved 94.2% accuracy for continuous optical measurement of blood pCO₂, aligning with clinical needs within a 7 mmHg threshold versus blood gas analyzers.
The company has decoupled HYLA from its life-support hardware so it can operate as a standalone, “universally compatible” system that integrates into existing heart-lung machines and ICU workflows, aiming at an approximately $50 billion heart-lung surgery market and a recurring revenue model from disposable sensors and software upgrades.
Management states this validation supports a planned U.S. FDA regulatory submission process in 2026. The update fits into Inspira’s broader strategy around its FDA-cleared INSPIRA™ ART100 cardiopulmonary bypass system, development of the ART500 platform, and expansion into blood-based diagnostics, including a proposed liquid biopsy acquisition.
Inspira Technologies reported that its FDA-cleared INSPIRA™ ART100 system has completed full clinical evaluation at a leading U.S. academic medical center ranked among the top hospitals in the country. The system treated approximately 30 patients across procedures such as life-saving interventions, surgeries and transplants.
Based on consistent performance and repeat use by medical staff, ART100 has moved from pilot use into the center’s standard clinical workflow, with no remaining open clinical evaluation phase. The hospital has started an internal, budgeted procurement process for multiple ART100 systems, subject to procedural budget release, which the company views as an important validation of ART100’s clinical value and commercial readiness.
Inspira Technologies reported procedural progress on two previously announced binding purchase orders of $22.5 million and $27 million. The company’s distribution partner notified Inspira that these orders have moved to the final governmental budgetary validation and fund allocation stage within the relevant authorities’ procurement processes.
Approximately 91% of the purchase order value has passed commercial and administrative review and is now in the last budgetary authorization step before funds can be released and operations executed, subject to customary governmental approvals. Inspira reiterated that payment and revenue recognition related to these orders are expected during the 2026 fiscal cycle, in line with the governmental budget cycle and deployment milestones, and noted it has completed internal preparations for execution.
Limor Rozen has filed a Form 144 to sell additional shares of issuer IINN. The notice covers 4,701 ordinary shares to be sold through Oppenheimer & Co. Inc. on NASDAQ, with an aggregate market value of $4,183.89. The filing notes that 24,252,096 ordinary shares were outstanding at the time of the notice.
The 4,701 shares to be sold were acquired on 11/01/2020 through an employee stock option plan and are to be paid for in cash upon exercise on 01/15/2026. The form also reports that during the past three months, Limor Rozen sold 14,999 ordinary shares on 10/22/2025 for gross proceeds of $15,898.94 and 10,730 ordinary shares on 11/12/2025 for gross proceeds of $10,856.61.
Inspira Technologies Oxy B.H.N. Ltd. filed an amended report detailing a planned acquisition and related financing with Bio-View Ltd.. Inspira entered a non-binding term sheet to acquire Bio-View’s liquid biopsy business in exchange for 40% of Inspira’s issued and outstanding share capital on a fully diluted basis. As part of the same transaction, Inspira expects a $15 million equity investment at a pre-money valuation of $180 million, with the acquisition and investment intended to close at the same time.
Existing Inspira shareholders as of a record date before closing will receive contingent value rights tied to net proceeds from any sale of Inspira’s current business assets. Inspira plans to use up to $12 million of the equity proceeds to fund these legacy operations, with Bio-View potentially entitled to amounts above $5 million from eventual sale proceeds. In connection with the term sheet, Inspira agreed to lend Bio-View $1 million via a senior convertible debenture bearing 10% annual interest, rising to 18% upon default, maturing after 180 days and convertible into Bio-View ordinary shares at NIS 0.30 per share, subject to Tel Aviv Stock Exchange approval and a 19.99% ownership cap.
Inspira Technologies Oxy B.H.N. Ltd. outlines a strategic vision and proposed transaction framework to expand into breast cancer liquid biopsy diagnostics through a contemplated acquisition of an advanced liquid biopsy platform and a concurrent $15 million equity investment. The liquid biopsy technology focuses on analyzing intact circulating tumor cells from blood, initially targeting breast cancer with potential extension to other solid tumors and companion diagnostic uses. Inspira plans to allocate up to $12 million from the equity investment to support and expand its existing respiratory and blood-monitoring platforms, including the FDA-cleared INSPIRA ART100 system and HYLA blood sensor. The transaction is structured to preserve shareholder value, including a contingent value rights framework and an intent to enable future dividend distributions from the Company’s core technologies.
Inspira Technologies Oxy B.H.N. Ltd. is offering 1,565,217 ordinary shares in a registered direct offering to a single institutional and accredited investor at $1.15 per share. The company expects net proceeds of approximately $1.7 million, which it plans to use for working capital and general corporate purposes.
Ordinary shares outstanding were 34,150,987 as of December 11, 2025, and are expected to be 35,716,204 after the offering. Inspira is a specialty medical device company developing life support technologies, including its FDA‑cleared INSPIRA ART100 cardiopulmonary bypass system, the investigational INSPIRA ART respiratory support platform, and the HYLA blood sensor.
The prospectus highlights significant risks, including a going concern explanatory paragraph in its 2024 audited financial statements, potential dilution from future equity issuances, share price volatility, and dependence on maintaining Nasdaq listing requirements. The company also notes operational and geopolitical risks related to its primary operations in Israel amid regional conflicts.
Inspira Technologies Oxy B.H.N. Ltd. entered into a definitive agreement for a registered direct offering of 1,565,217 ordinary shares at $1.15 per share, expected to generate gross proceeds of $1.8 million for the company. The shares will be issued under an effective Form F-3 shelf registration, with closing expected on or about December 16, 2025, and net proceeds earmarked for working capital and general corporate purposes.
The company also signed a Standby Equity Purchase Agreement with YA II PN, Ltd., allowing it to sell up to $25 million of ordinary shares over 36 months at 97% of the market price, based on the lowest daily VWAP over a three-day period following an Advance Notice. YA cannot purchase shares that would take its ownership above 4.99%. Inspira will pay a 2% commitment fee in ordinary shares priced at $1.15 and a $25,000 structuring fee, and intends to use any SEPA proceeds for working capital and general corporate purposes.